Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CNTY
CNTY logo

CNTY Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Century Casinos Inc (CNTY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.450
1 Day change
4.32%
52 Week Range
2.850
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Century Casinos Inc (CNTY) is not a strong buy for a beginner, long-term investor at this moment. The company's financial performance is weak, with significant declines in net income, EPS, and gross margin. Technical indicators do not suggest a clear upward trend, and there are no recent positive news or significant catalysts. While options data shows a relatively low Open Interest Put-Call Ratio (0.46), indicating bullish sentiment, the lack of strong trading signals and weak financials make this stock a hold rather than a buy.

Technical Analysis

The MACD is slightly positive but expanding, indicating mild bullish momentum. However, the RSI is neutral (43.989), and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upside potential in the short term, with resistance at 1.521 and support at 1.272.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
7

Positive Catalysts

  • Analysts have maintained a Buy rating and raised price targets, citing potential for lead asset CNTY-813.

Neutral/Negative Catalysts

  • Weak financial performance in Q4 2025, with a 72.35% YoY drop in net income and a 71.09% YoY drop in EPS. Gross margin fell to 0, indicating significant operational challenges. No recent news or congress trading data to support positive sentiment.

Financial Performance

In Q4 2025, revenue increased slightly by 0.16% YoY to $137.99M, but net income dropped by 72.35% YoY to -$17.95M. EPS fell by 71.09% YoY to -0.61, and gross margin dropped to 0, reflecting poor profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are cautiously optimistic, with Piper Sandler raising the price target to $4 from $2 and maintaining an Overweight rating. Clear Street lowered the price target to $6.60 from $8 but maintained a Buy rating, citing dilution offset by increased pipeline success likelihood.

Wall Street analysts forecast CNTY stock price to rise
2 Analyst Rating
Wall Street analysts forecast CNTY stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.450
sliders
Low
4
Averages
4
High
4
Current: 1.450
sliders
Low
4
Averages
4
High
4
Piper Sandler
NULL
to
Overweight
upgrade
$2 -> $4
AI Analysis
2026-01-20
Reason
Piper Sandler
Price Target
$2 -> $4
AI Analysis
2026-01-20
upgrade
NULL
to
Overweight
Reason
Piper Sandler raised the firm's price target on Century Therapeutics to $4 from $2 and keeps an Overweight rating on the shares. The firm notes Century plans to submit an IND for CNTY-813 this year and report initial data in 2027. Piper estimates Century now hold pro forma cash of about $267M to fund operations into Q1 2029.
Clear Street
Bill Maughan
Buy
downgrade
$8
2026-01-08
Reason
Clear Street
Bill Maughan
Price Target
$8
2026-01-08
downgrade
Buy
Reason
Clear Street analyst Bill Maughan lowered the firm's price target on Century Therapeutics to $6.60 from $8 and keeps a Buy rating on the shares. The private placement brings the runway out to 1Q29, allowing for development of a fuller picture of the true potential of lead asset CNTY-813 before needing additional capital, the analyst tells investors in a research note. The firm added that it is reducing its price target on dilution from the raise, offset by increased pipeline likelihood of success and peak sales.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CNTY
Unlock Now

People Also Watch